A phase Ib/II study investigating the safety and efficacy of capmatinib plus gefitinib in patients with EGFR-mutated and MET-dysregulated (amplified/overexpressing) NSCLC revealed an ORR of 47% in patients with a MET gene copy number ≥6 with tolerable toxicity [63]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.